The number of treatment options continues to increase in the T1D space. Existing agents fail to provide sustained and intrinsic control of T1D, and none address the autoimmune component of T1D’s etiology. The emphasis has shifted on the types of therapies in development for T1D, with a significant interest in immune modulation and cell-based therapies. The launch of biosimilar insulins is creating pricing pressure on branded originators in the major markets and giving payers greater leverage to negotiate price.

QUESTIONS ANSWERED

  • How will endocrinologists differentiate between the emerging therapies, and which agents will enjoy the greatest clinical and commercial success in an increasingly stringent regulatory and cost-sensitive environment?
  • What impact will the increasing use of insulin pumps have on market dynamics?
  • What will be the market impact of biosimilar insulins? How resistant are physicians to payer pressure to switch patients to biosimilar insulin?
  • What role will SGLT inhibitors and immunomodulators play in the evolving T1D treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Type 1 Diabetes - Key Findings - December 2019
    • Key Updates
      • December 2019
      • September 2019
      • June 2019
      • March 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Type 1 Diabetes?
        • What Factors Are Constraining the Market for Type 1 Diabetes?
      • Drug-Class Specific Trends
        • Insulins
        • SGLT Inhibitors
        • Immunomodulators
    • Forecast
      • Market Forecast Assumptions - Type 1 Diabetes 2018-2028 - December 2019
      • Market Forecast Dashboard - Type 1 Diabetes 2018-2028 - December 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
        • Etiology
      • Pathophysiology
        • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Type 1 Diabetes
        • Drug-Treated Cases of Type 1 Diabetes
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Insulins
        • SGLT Inhibitors
        • Amylin Analogues
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Type 1 Diabetes
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Insulins
        • SGLT Inhibitors
        • Immunomodulators
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Type 1 Diabetes Bibliography

Author(s): Kerri Brown, M Pharm; Joseph Granato, MPH

Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.

Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access ; Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the ; He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health. He received his from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne ; He also holds a in Animal Science from the University of ; Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.


Related Reports

Type 1 Diabetes | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 1 diabetes ...

View Details

Type 1 Diabetes | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms, Claims Data Analysis (US)

Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown...

View Details